Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CTT Pharmaceutical HoldingsCTTH -0.13% ROA % is -196.23% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 1,009 Drug Manufacturers companies, CTT Pharmaceutical Holdings ranks worse than 97.13% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. CTT Pharmaceutical Holdings's annualizedNet Income for the quarter that ended in Dec. 2025 was $-0.16 Mil.
CTT Pharmaceutical Holdings's average Total Assets over the quarter that ended in Dec. 2025 was $0.08 Mil. Therefore, CTT Pharmaceutical Holdings's annualized ROA % for the quarter that ended in Dec. 2025 was -196.23%.
The historical rank and industry rank for CTT Pharmaceutical Holdings's ROA % or its related term are showing as below:
CTTH'
s ROA % Range Over the Past 10 Years
Min: -196.23 Med: -81.23 Max: 137.34
Current: -196.23
During the past 13 years, CTT Pharmaceutical Holdings's highest ROA % was 137.34%. The lowest was -196.23%. And the median was -81.23%.
CTTH's ROA % is ranked worse than 97.13% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 2.74
vs CTTH: -196.23
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is one times the annual (Dec. 2025) net income data. The Revenue data used here is one times the annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CTT Pharmaceutical Holdings's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CTT Pharmaceutical Holdings ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CTT Pharmaceutical Holdings's ROA % distribution charts can be found below:
* The bar in red indicates where CTT Pharmaceutical Holdings's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is one times the annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
CTT Pharmaceutical Holdings (CTTH) has a ROA % of -196.23% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on CTT Pharmaceutical Holdings and its competitors. According to the industry distribution chart, CTT Pharmaceutical Holdings ranks #980 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 97.1%.
Is CTT Pharmaceutical Holdings' ROA % too high?
CTT Pharmaceutical Holdings' current ROA % is -196.23%. Based on the distribution chart, CTT Pharmaceutical Holdings ranks #980 out of 1009 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does CTT Pharmaceutical Holdings' ROA % compare to BUDZ and SBFM?
According to the Drug Manufacturers industry distribution chart, CTT Pharmaceutical Holdings ranks #980 out of 1009 companies for ROA %. This places CTT Pharmaceutical Holdings in the lower half of its industry. The industry median ROA % is 2.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.74, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on CTT Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CTT Pharmaceutical Holdings's current ROA % is -196.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CTT Pharmaceutical Holdings stock overvalued right now?
CTT Pharmaceutical Holdings (CTTH) has a current ROA % of -196.23%. The current ROA % is -196.23%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For CTT Pharmaceutical Holdings (CTTH), the current ROA % is -196.23% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CTT Pharmaceutical Holdings Inc specializes in drug delivery systems technology within the pharmaceutical industry. Its focus is on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The company's technology platform includes the development of oral delivery thin wafers to deliver treatment as an alternative to smoking and ingestion. This technology platform target both the human and veterinarian(pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in majorly markets such as pain management and smoking cessation. The Oral Thin Film formulation is protected by patents in the USA, Canada, Europe and many other countries across the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTTH has been successfully added to your 
